Study S002201

Cardioprotective Effects of Exenatide in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention ; Results of Exenatide Myocardial Protection In REvascularization (EMPIRE) Study

ClinicalTrials.gov record

Registration

Registration: NCT01580514
Acronym: EMPIRE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: COMPLETED
Enrollment: 127
Start: 2009-09
Primary completion: 2011-08
Lead sponsor: Kyunghee University Medical Center
Conditions: Myocardial Infarction
Interventions: DRUG:exenatide BYETTA® (Amylin-Lilly); DRUG:Saline
Results posted: FALSE

Registered primary outcomes

Infarct size [1 month]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025816	Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials. Huang M, Annals of medicine	2017	Systematic review	PMID 28286967 DOI	cites ClinicalTrials.gov:NCT01580514; registry reference DERIVED:28286967
R0026296	Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Woo JS, Arteriosclerosis, thrombosis, and vascular biology	2013	Randomized trial	PMID 23868944 DOI	cites ClinicalTrials.gov:NCT01580514; registry reference DERIVED:23868944
R0025460	Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. Timmers L, Journal of the American College of Cardiology	2009	Randomized trial	PMID 19195607 DOI	registry reference BACKGROUND:19195607